65 results about "Mental illness" patented technology

The invention discloses a mental disease classification method fusing prior knowledge and a multi-mode self-attention mechanism, and belongs to the technical field of medical image processing. In order to solve the problems that in the current mental disease classification process, biomarker information is dispersed, and reproducibility is insufficient, multi-mode nerve image data, field priori knowledge and the intelligent analysis ability of a large language model are fully fused, and existing mental disease biomarkers are integrated, optimized and utilized. And related medical knowledge is efficiently extracted and integrated by using a large language model, so that efficient and accurate classification of mental diseases is realized. The method provides an innovative technical path and theoretical support for precise diagnosis and mechanism research of mental disorders.

The invention relates to bacteria of the species Lactobacillus paracasei and / or compositions comprising Lactobacillus paracasei for use in preventing and / or treating a mental illness, a symptom affecting mental health and / or a condition associated with chronic stress, in a mammal. The invention further relates to methods and uses of said bacteria of the species Lactobacillus paracasei and / or compositions. The invention can be applied in restoring, maintaining, and / or promoting mental (including cognitive) health and has potential applications, inter alia, in the area of dietary and food supplements, medicaments and pharmaceuticals.

The application discloses a mental health evaluation method and system based on brain area electric stimulation, relates to the technical field of medical and health information science, and creatively integrates brain area electric stimulation into mental health evaluation. The basic cognitive level and neural plasticity potential of a measured person are objectively quantified through comprehensive scores before and after brain area electric stimulation, so that corresponding suitable mental health evaluation test questions are selected based on the basic cognitive level and neural plasticity potential, and the precision, sensitivity of corresponding mental tests and the mental comfort of the measured person are significantly improved. A decay quantization model of a stimulating current from an electrode to the brain is given, the decay quantization model is used to accurately control the electric quantity, and the maximum beneficial effect is realized under the condition of guaranteeing health and safety. Historical data accumulated in the application process can be effectively used to solve medical problems, such as the influence of brain area electric stimulation on child neural development evaluation, early warning of mental illness and brain function reinforcement.

The mental illness recognition system based on the optical flow features collected by a visual sensor comprises a mental illness expert consultation video data preprocessing module, a facial stress unit extraction module, an optical flow change feature unit construction module, a classification model construction module and a patient mental illness category recognition module connected in sequence. The mental illness expert consultation video data preprocessing module feeds the patient facial picture to the facial stress unit extraction module. The facial stress unit extraction module feeds the optical flow calculation method and the patient facial picture sequence to the optical flow change feature unit construction module. The optical flow change feature unit construction module feeds the optical flow change feature unit to the classification model construction module and the patient mental illness category recognition module respectively. The classification model construction module feeds the classification model to the patient mental illness category recognition module. The mental illness and normal sample classification recognition is realized under the condition that the user facial video has good clarity.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The application discloses a kind of psychological disease pre-diagnosis information processing method and system, method includes: the multi-modal behavior signal and physiological parameter signal of user are collected, and respectively carry out the differential privacy protection processing based on edge computing and the noise separation processing based on wavelet transform, obtain standardized behavior characteristic sequence and time sequence physiological characteristic vector;Behavior node feature and psychological state marker are extracted from standardized behavior characteristic sequence, and three-dimensional association matrix is constructed in combination with time sequence physiological characteristic vector;Potential risk probability is calculated based on graph neural network model, generates pre-diagnosis grading result, and through gradual protocol fusion objective behavior environment data, output personalized intervention strategy, finally generate comprehensive pre-diagnosis report.The application realizes the accurate modeling of psychological-physiological-behavior dynamic association by dynamic knowledge graph construction and cross-modal fusion analysis, while giving consideration to data privacy protection, effectively improves the accuracy and practicality of mental health monitoring.

The present invention relates to a novel compound as a 5-HT 2A receptor inverse agonist, a method for preparing the same and a pharmaceutical composition. It also relates to the use of the compound or the pharmaceutical composition in the manufacture of a medicament for treating 5-HT 2A receptor related diseases, including non-motor symptoms of Parkinson's disease: delusions, hallucinations, depression, anxiety, cognitive impairment, sleep disorders; dementia-related psychiatric disorders; major depressive disorder; or negative symptoms of schizophrenia, etc.

Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The system according to the embodiment aims to analyze conversation data, detect signs of mental illness early, and provide appropriate advice. [Solution] A system according to an embodiment includes a collection unit, an analysis unit, a detection unit, and a provision unit. The collection unit collects conversation data. The analysis unit analyzes the data collected by the collection unit. The detection unit detects signs of mental illness based on the data analyzed by the analysis unit. The provision unit provides advice based on the signs detected by the detection unit.

The present disclosure relates to indole derivatives of general Formula (I), to processes for their preparation, to compositions including them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders, or conditions by activation of a serotonin receptors in a cell. The diseases, disorders, or conditions include, for example, psychosis, mental illnesses, and central nervous system (CNS) disorders.

Provided herein include compounds, compositions, kits and methods for preventing and treating psychiatric disorders. The composition and methods described herein can prophylactically treat a subject prior to and / or after a stressor and / or prior to the recurrence of a stressor, thereby preventing or delaying a relapse of depression or depression-like and / or stress-induced behaviors and disorders. The composition can comprise a serotonin 4 receptor (S-HUR) agonist and an N- methyl-D-aspartate (NMDAR) antagonist and a pharmaceutically acceptable salt, analog, derivative or metabolite thereof.

The invention relates to compositions comprising Lactobacillus plantarum, and methods and uses of said compositions for preventing and / or treating mental illness, symptoms affecting mental health and / or conditions associated with chronic stress, in a mammal. The invention can be applied in restoring, maintaining, and / or promoting mental (including cognitive) health and has potential applications, inter alia, in the area of dietary and food supplements, medicaments and pharmaceuticals.

The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as agonists or antagonists of the serotonin (5-HT2A) receptor, preferably non-hallucinogenic biased agonists at the serotonin (5-HT2A) receptor, such as having agonism biased towards the beta-arrestin signaling pathway. Such compounds are useful for the treatment of mood disorders, general anxiety, social anxiety, depression, and other neuropsychiatric diseases.

The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.

The application discloses a virus marker for depression diagnosis and a screening method and application thereof, relates to the technical field of biological detection, and the virus marker for depression diagnosis comprises at least one of s_Stenotrophomonas_virus_Pokken, g_Pokkenvirus, s_Dickeya_virus_AD1 and g_Alexandravirus. The application firstly takes the enterovirus group characteristics as the biomarker of depression, breaks through the limitation that traditional mental illness diagnosis relies on subjective scale evaluation; compared with the prior art, the four virus markers can be used for the diagnosis of clinical depression alone or in combination, have the characteristics of non-invasiveness and high sensitivity, can effectively distinguish the depression patients from the healthy people, can early discover the high-risk groups, and provide a new objective diagnosis method for the precise typing of depression.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The invention discloses a virus marker for depression diagnosis as well as a screening method and application of the virus marker, and relates to the technical field of biological detection, the virus marker for depression diagnosis comprises at least one of sStreptophomonasvirus Pokken, gPokenvirus, sDickeyavirus AD1 and gAlexanvirus, and the virus marker for depression diagnosis comprises at least one of sStreptophomonasvirus Pokken, gPokenvirus, sDickeyavirus AD1 and gAlexanvirus. According to the invention, enterovirome characteristics are used as the biomarker of depression for the first time, and the limitation that traditional mental disease diagnosis depends on subjective scale evaluation is broken through; compared with the prior art, the four virus markers can be independently or jointly used for clinical diagnosis of depression, have the characteristics of non-invasiveness and high sensitivity, can effectively distinguish depression patients from healthy people, can find high-risk people in an early stage, and provide a brand new objective diagnosis method for precise typing of depression.

1. Name of the design product: Scream instrument. 2. Use of the design product: for treating mental illness, venting and screaming. 3. Design points of the design product: in shape. 4. Picture or photo that best shows the design points: perspective view 1.

The invention discloses application of volatile components of Chuzhou chrysanthemum in preparation of medicines for treating depression and cognitive impairment. The volatile component of the Chuzhou chrysanthemum can be applied to preparation of drugs for treating depression; or preparing a medicine for treating cognitive impairment; or preparing a medicine for protecting neuroendocrine cells; or preparing medicines for treating nervous system diseases. The active ingredients are completely derived from the traditional medicinal plant Chuzhou chrysanthemum, and cell experiments prove that the active ingredients are non-toxic to nerve cells under the effective concentration (less than or equal to 50 mu g / mL) and can antagonize the damage effect of CORT. And compared with a synthetic drug, the anticipated side effect is smaller, and the patient compliance is better. According to the invention, it is found through molecular docking that Z-alpha-trans-bergamot alcohol and bornyl isovalerate have very strong binding activity with core targets EGFR and MAOB for the first time, the two compounds can be deeply developed as brand new lead compounds for treating neurological and mental diseases, and drug sources are expanded.

The present invention relates to an amphiphilic block copolymer represented by formula I, a preparation method thereof, and a nanomicelle drug delivery system formed from the copolymer and a poorly soluble drug. The amphiphilic block copolymer includes a hydrophilic chain segment, a hydrophobic chain segment, and a linker for linking the hydrophilic chain segment to the hydrophobic chain segment. The linker contains an unsaturated structure, which can enhance the interaction between the poorly soluble drug and the copolymer to improve the drug loading ability and stability of the nanomicelle. The invention also relates to a nanomicelle drug-loading system, a preparation method thereof, and the use of the nanomicelle drug-loading system for preparing medicines for treating tumors, inflammation, diabetes, central nervous system diseases, cardiovascular diseases, and psychological disorders.

The invention relates to application of 4 '-demethyl epipodophyllotoxin or a medicinal derivative thereof in depression resistance, and belongs to the technical field of biological medicines. Depression is a serious nervous and mental disease and affects millions of people in the world. Major depression is the most common mental disorder and is also one of the main causes of global disability. Depression is considered to be a complex disease caused by interaction of genetic, physiological, psychological and environmental factors. It is found that the novel antidepressant drug capable of treating depression has great significance. A per2- / -mutant zebrafish depression model is utilized to perform drug screening on traditional Chinese medicine monomers, and finally, 10 mu M of 4 '-demethylepipodophyllotoxin has an anti-depression characteristic and can effectively improve the depression-like phenotype of per2- / -mutant zebrafish. A medicinal plant podophyllotoxin from which 4 '-demethyl epipodophyllotoxin is extracted is safe and non-toxic, and no report about 4'-demethyl epipodophyllotoxin depression resistance exists at present.

The application relates to a spatio-temporal fusion neural network construction method, which comprises the following steps: constructing a DFC network; calculating a functional connection matrix to form a dynamic functional connection network; modeling the functional connection matrix corresponding to each time window into a graph structure to obtain a series of graph structures, and realizing dynamic functional connection construction; constructing a multi-granularity brain network; realizing spatio-temporal feature extraction; obtaining a dynamic functional connection analysis result; performing feature extraction, averaging the features of all time steps to obtain a global feature representation, obtaining a final output feature, and obtaining an fMRI time sequence analysis result; splicing the dynamic functional connection analysis result and the fMRI time sequence analysis result together to form a final feature representation; and outputting a prediction label to realize multi-scale feature fusion. The application also relates to a spatio-temporal fusion neural network construction system. The application can synchronously extract and deeply fuse spatio-temporal features, and comprehensively improve the accuracy and robustness of mental disease recognition.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The present application relates to the technical field of medical equipment, in particular to a wearable restraint device for patients with mental illness, comprising a winding assembly, a restraint assembly, a fixing assembly and a connecting belt, the connecting belt is movably penetrated in the winding assembly, one end of the connecting belt extends to one side and is fixed with the restraint assembly, the other end of the connecting belt extends to the other side and is fixed with the fixing assembly, two stop blocks are arranged at intervals in the length direction of the connecting belt, and the two stop blocks are respectively arranged on the two sides of the winding assembly and form a stop cooperation with the winding assembly; in use, the restraint assembly can be sleeved on the patient's limbs, the fixing assembly can be sleeved on the preset position, for example, the fixing assembly can be sleeved on the rail of the bed body, so as to form a restraint state, and the tightness of the connecting belt is adjusted through the winding assembly, so as to adaptively adjust the restraint force.

1. Name of the product in this design: Transcranial Direct Current Stimulation Therapy Device (TDCS). 2. Purpose of this design: For adjunctive treatment of mental illness and neurological rehabilitation. 3. The key design feature of this product is its shape. 4. Images or photos that best illustrate the design key points: Use a combination of state diagrams.

The present invention relates to methods and pharmaceutical compositions effective for treating, inhibiting, alleviating, slowing or delaying the onset of a mental disease in a mammal, such as a human, by administering an effective amount of a compound selected from Formula (I), Formula (II), Formula (III) or Formula (IV) or a pharmaceutically acceptable salt thereof. In certain embodiments, the present invention relates to methods and pharmaceutical compositions of an effective amount of a compound selected from the group consisting of Formula (I), Formula (II), Formula (III), or Formula (IV), or a pharmaceutically acceptable salt thereof, and an effective amount of an antipsychotic agent, an antidepressant agent, a magical agent, and combinations thereof. In certain embodiments, the mental disorder is autism, attention deficit hyperactivity disorder, bipolar affective disorder, severe depressive disorder, or schizophrenia.